View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 16, 2022

MAIA Biotechnology to commence Phase II NSCLC treatment trial

The trial will analyse the possible immune system activation effects of THIO followed by cemiplimab in subjects with NSCLC.

MAIA Biotechnology is set to commence the Phase II THIO-101 clinical trial of its lead compound, 6-thio-dG or 6-thio-2’-deoxyguanosine (THIO), followed by cemiplimab in advanced non-small cell lung cancer (NSCLC) patients. 

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The move comes after the company obtained approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to launch the trial.

The trial will analyse the possible immune system activation effects of THIO followed by cemiplimab in subjects with NSCLC, to permit immune activation and PD-1 sensitivity to occur.

It will assess if low dosages of THIO given before checkpoint inhibitor could boost and extend immune response in advanced NSCLC patients who were unresponsive to or have advanced following first-line treatment regimen comprising a checkpoint inhibitor. 

Analysing the safety of THIO given as an anticancer agent and a priming immune system agent before administration of cemiplimab is one of the primary objectives of the trial.

Evaluating the clinical efficacy of THIO given followed by cemiplimab assessed using overall response rate as the primary clinical endpoint will be the other objective.

In the initial stage, the trial will be initiated in Australia and Europe with plans to extend it to the US.

A telomere-targeting agent, THIO is in the development stage as a second or later line of NSCLC therapy for patients who have advanced beyond the current standard-of-care regimen of checkpoint inhibitors.

Telomeres, together with the enzyme telomerase, plays a crucial role in cancer cell survival and resistance to existing treatments.

Cemiplimab is a checkpoint inhibitor developed jointly by Regeneron and Sanofi.

MAIA Biotechnology Clinical Development head and chief medical officer Mihail Obrocea said: “We are thrilled to receive the Ethics Committee approval to proceed with our Phase II clinical study, THIO-101, in Australia. 

“Our approach to treating NSCLC patients with THIO is unique – we look forward to exploring the utility of THIO as a lead-in agent for checkpoint inhibitors, which we believe will enhance and extend the immune system’s response, allowing for a more effective and targeted therapeutic approach.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU